Skip to main content

Vincristine liposome Side Effects

Medically reviewed by Last updated on Aug 16, 2023.

Applies to vincristine liposome: intravenous suspension.


Intravenous route (Suspension)

VinCRIStine sulfate liposome is for IV use only and is fatal if given by other routes. Death has occurred with intrathecal use. VinCRIStine sulfate liposome injection has different dosage recommendations than vinCRIStine sulfate injection. Verify drug name and dose before preparation and administration to avoid overdosage.

Serious side effects

Along with its needed effects, vincristine liposome may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking vincristine liposome:

More common

Less common

Other side effects

Some side effects of vincristine liposome may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to vincristine liposome: intravenous kit.


Common (1% to 10%): Hypotension, cardiac arrest, vascular disorder[Ref]


Very common (10% or more): Nausea (52%), diarrhea (37%), decreased appetite (33%)

Common (1% to 10%): Constipation, abdominal pain, ileus/colonic pseudo-obstruction[Ref]


Side effects that have resulted in non-leukemia related deaths: Brain infarct, intracerebral hemorrhage, liver failure, multisystem organ failure, pneumonia and septic shock, respiratory failure, pulmonary hemorrhage, sudden cardiac death[Ref]


Very common (10% or more): Febrile neutropenia (38%), neutropenia (31.3%), anemia (34%), thrombocytopenia (16.9%)

Frequency not reported: Neutropenia, thrombocytopenia[Ref]


Frequency not reported: Increased aspartate aminotransferase, tumor lysis syndrome[Ref]


Frequency not reported: Asthenia, muscular weakness, musculoskeletal pain[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (39%), insomnia (32%)

Common (1% to 10%): Peripheral sensory and motor neuropathy, decreased vibratory sense, facial palsy, hyporeflexia, asthenia[Ref]


Very common (10% or more): Pyrexia (15%), fatigue (12%)[Ref]


Frequency not reported: Mental status changes[Ref]


Common (1% to 10%): Respiratory distress, respiratory failure, pneumonia[Ref]


Common (1% to 10%): Septic shock, staphylococcal bacteremia[Ref]


Frequency not reported: Extravasation tissue injury[Ref]


Frequency not reported: Hepatic toxicity[Ref]


Very common (10% or more): Pyrexia (43%), fatigue (41%)

Frequency not reported: Pain, septic shock, staphylococcal bacteremia[Ref]


1. "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.